CN116687891B - Application of phenyl selenium chloride - Google Patents
Application of phenyl selenium chloride Download PDFInfo
- Publication number
- CN116687891B CN116687891B CN202310835197.XA CN202310835197A CN116687891B CN 116687891 B CN116687891 B CN 116687891B CN 202310835197 A CN202310835197 A CN 202310835197A CN 116687891 B CN116687891 B CN 116687891B
- Authority
- CN
- China
- Prior art keywords
- staphylococcus aureus
- chloride
- compound
- pseudomonas aeruginosa
- phenylselenium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WJCXADMLESSGRI-UHFFFAOYSA-N phenyl selenohypochlorite Chemical compound Cl[Se]C1=CC=CC=C1 WJCXADMLESSGRI-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 21
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 12
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 239000000969 carrier Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 10
- 230000005764 inhibitory process Effects 0.000 abstract description 10
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 150000002611 lead compounds Chemical class 0.000 abstract description 4
- 229940124350 antibacterial drug Drugs 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 244000000007 bacterial human pathogen Species 0.000 description 5
- -1 compound phenyl selenium chloride Chemical class 0.000 description 5
- 239000006391 Luria-Bertani Medium Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 206010051548 Burn infection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 244000000023 zoonotic pathogen Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides application of a phenylselenium chloride compound in preparation of anti-human pathogenic bacteria medicines, and the phenylselenium chloride compound can be found to be capable of effectively inhibiting the growth of staphylococcus aureus and pseudomonas aeruginosa through evaluation of the antibacterial activity of the phenylselenium chloride, wherein the inhibition rate is more than 70%, which indicates that the phenylselenium chloride has strong antibacterial activity on the staphylococcus aureus and the pseudomonas aeruginosa. The compound can be used as a lead compound for preparing antibacterial drugs, and can be used for treating diseases caused by staphylococcus aureus and pseudomonas aeruginosa.
Description
Technical Field
The invention relates to the field of medicines, in particular to application of phenyl selenium chloride.
Background
Pathogenic microorganisms are easy to cause infectious and food-borne diseases and seriously harm the health of people. Staphylococcus aureus (staphylococcus aureus) is used as a common food-borne pathogenic microorganism, can pollute meat products, dairy products, bean products and foods with high starch content, can cause food poisoning of people, is easy to cause respiratory tract infection of human bodies, can cause pneumonia, can cause suppurative infection of soft tissues of the human bodies, and even can cause diseases such as septicemia and the like of the human bodies when serious.
Pseudomonas aeruginosa is also a common zoonotic pathogen. Pseudomonas aeruginosa can be parasitic to the skin, eyes, ears and urethra of humans and animals. Pseudomonas aeruginosa has strong toxicity and can cause burn infection, pneumonia and urinary infection of human body. Especially for people with weak resistance.
There is currently a lack of technical content related to the inhibition of staphylococcus aureus and pseudomonas aeruginosa by phenylselenium chloride.
Disclosure of Invention
Aiming at the defects existing in the prior art, the invention aims to provide application of phenyl selenium chloride to solve the problems in the background art, and the application of the compound phenyl selenium chloride in resisting human pathogenic bacteria.
In order to achieve the above object, the present invention is realized by the following technical scheme: the phenylselenium chloride is applied to the preparation of medicaments for inhibiting human pathogenic bacteria.
Further, the human pathogenic bacteria include staphylococcus aureus and pseudomonas aeruginosa; the medicine for inhibiting human pathogenic bacteria comprises pharmaceutically acceptable auxiliary materials and carriers.
Furthermore, the phenyl selenium chloride compound is applied to the preparation of antibacterial drugs and is used as a lead compound.
The invention has the beneficial effects that:
1. according to the invention, through evaluation of the antibacterial activity of the phenylselenium chloride, the compound can effectively inhibit the growth of staphylococcus aureus and pseudomonas aeruginosa, and the inhibition rate reaches more than 70%. The phenyl selenium chloride has strong antibacterial activity on staphylococcus aureus and pseudomonas aeruginosa.
2. The phenylselenium chloride compound can be used as a lead compound for preparing antibacterial medicines.
Drawings
FIG. 1 is a phenyl selenium chloride structural formula;
FIG. 2 shows the inhibition of Staphylococcus aureus by phenylselenium chloride at various concentrations;
FIG. 3 shows the inhibition of P.aeruginosa by phenylselenium chloride at various concentrations;
FIG. 4 is a graph showing the inhibition of Staphylococcus aureus by 500 μg/mL phenylselenium chloride;
FIG. 5 shows the inhibition of P.aeruginosa by 500 μg/mL phenylselenium chloride.
Detailed Description
The invention is further described in connection with the following detailed description, in order to make the technical means, the creation characteristics, the achievement of the purpose and the effect of the invention easy to understand.
Referring to fig. 1 to 5, the present invention provides a technical solution: the application of phenyl selenium chloride compound in preparing medicine for resisting human pathogenic bacteria. The antibacterial activity of the p-phenylselenium chloride compound is evaluated, and the compound is found to be capable of effectively inhibiting the growth of staphylococcus aureus and pseudomonas aeruginosa, and the inhibition rate is more than 70%. The phenyl selenium chloride compound has strong antibacterial activity on staphylococcus aureus and pseudomonas aeruginosa. The compound can be used as a lead compound for preparing antibacterial medicines.
As shown in fig. 2 and 4, the antibacterial activity test shows that phenylselenium chloride can effectively inhibit the growth of staphylococcus aureus. At the concentration of 500 mug/mL, the inhibition rate of the phenylselenium chloride to staphylococcus aureus reaches 82.33%; as shown in fig. 3 and 5, the antibacterial activity test shows that the phenylselenium chloride can effectively inhibit the growth of pseudomonas aeruginosa. At a concentration of 500 mug/mL, the inhibition rate of the phenylselenium chloride on the pseudomonas aeruginosa reaches 70.33 percent.
The experiment mainly comprises the following contents:
1. effect of phenylselenium chloride Compounds on Staphylococcus aureus growth
Staphylococcus aureus was incubated at 37℃at 180rpm in Luria-Bertani medium (10 g peptone, 5g yeast extract, 10g NaCl in 1L deionized water, pH adjusted to 7.0, and sterilized at 121℃for 20 minutes).
And (3) paving: 100 mu L of fully fermented staphylococcus aureus culture solution is taken and added into a 96-well plate;
adding the medicine: the compound phenylselenium chloride is diluted into mother liquor with the concentration of 10mg/mL by sterile deionized water for standby. 20 mu L of compound phenylselenium chloride mother liquor with different concentrations is respectively taken and added into 100 mu L of bacterial liquid, and 20 mu L of sterile deionized water is added into 100 mu L of bacterial liquid to serve as a control. Then 80. Mu.L of Luria-Bertani medium was added thereto, and the culture was continued at 37℃for 24 hours.
And (3) detection: the absorbance was measured in an ELISA at a wavelength of 600 nm.
2. Effect of phenyl selenium chloride Compounds on Pseudomonas aeruginosa growth
Pseudomonas aeruginosa was cultured in Luria-Bertani medium (10 g peptone, 5g yeast extract, 10g NaCl in 1L deionized water, pH was adjusted to 7.0, and sterilized at 121℃for 20 minutes) at 37℃at 180 rpm.
And (3) paving: 100 mu L of fully fermented staphylococcus aureus culture solution is taken and added into a 96-well plate;
adding the medicine: the compound phenylselenium chloride is diluted into mother liquor with the concentration of 10mg/mL by sterile deionized water for standby. 20 mu L of compound phenylselenium chloride mother liquor with different concentrations is respectively taken and added into 100 mu L of bacterial liquid, and 20 mu L of sterile deionized water is added into 100 mu L of bacterial liquid to serve as a control. Then 80. Mu.L of Luria-Bertani medium was added thereto, and the culture was continued at 37℃for 24 hours.
And (3) detection: the absorbance was measured in an ELISA at a wavelength of 600 nm.
While the fundamental and principal features of the invention and advantages of the invention have been shown and described, it will be apparent to those skilled in the art that the invention is not limited to the details of the foregoing exemplary embodiments, but may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. Any reference sign in a claim should not be construed as limiting the claim concerned.
Furthermore, it should be understood that although the present disclosure describes embodiments, not every embodiment is provided with a separate embodiment, and that this description is provided for clarity only, and that the disclosure is not limited to the embodiments described in detail below, and that the embodiments described in the examples may be combined as appropriate to form other embodiments that will be apparent to those skilled in the art.
Claims (2)
1. The application of phenyl selenium chloride in preparing a medicament for inhibiting staphylococcus aureus or pseudomonas aeruginosa is characterized in that: the phenylselenium chloride is applied to the preparation of medicaments for inhibiting staphylococcus aureus or pseudomonas aeruginosa.
2. The use according to claim 1, characterized in that: the medicament comprises pharmaceutically acceptable auxiliary materials or carriers.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310835197.XA CN116687891B (en) | 2023-07-10 | 2023-07-10 | Application of phenyl selenium chloride |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310835197.XA CN116687891B (en) | 2023-07-10 | 2023-07-10 | Application of phenyl selenium chloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116687891A CN116687891A (en) | 2023-09-05 |
| CN116687891B true CN116687891B (en) | 2024-01-19 |
Family
ID=87825794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310835197.XA Active CN116687891B (en) | 2023-07-10 | 2023-07-10 | Application of phenyl selenium chloride |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116687891B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110771623A (en) * | 2019-10-14 | 2020-02-11 | 东华大学 | Preparation method of mesoporous silica long-acting antibacterial nanomaterial with high selenium loading |
-
2023
- 2023-07-10 CN CN202310835197.XA patent/CN116687891B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110771623A (en) * | 2019-10-14 | 2020-02-11 | 东华大学 | Preparation method of mesoporous silica long-acting antibacterial nanomaterial with high selenium loading |
Non-Patent Citations (5)
| Title |
|---|
| "Attachment of organo-selenium to polyamide composite reverse osmosis membranes to inhibit biofilm formation of S. aureus and E. coli";Tony Vercellino，等.;《Desalination》;第309卷;第291-295页 * |
| "Attachment of selenium to a reverse osmosis membrane to inhibit biofilm formation of S. aureus";Low D, Hamood A, Reid T, 等;《J Memb Sci》;第378卷(第1期);第171-178页 * |
| "PhSeZnCl in the Synthesis of Steroidal -Hydroxy-Phenylselenides Having Antibacterial Activity";Izabella Jastrzebska, 等.;《International Journal of Molecular Science》;第20卷(第9期);第1-13页 * |
| "富硒枸杞子对临床常见分离耐药菌体外抑菌活性的研究";马锐等.;《检验医学与临床》;第11卷(第5期);第581-582页 * |
| "微量元素硒对金黄色葡萄球菌的抑制作用";李咏梅等.;《吉林医学院学报》;第19卷(第1期);第3-4页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116687891A (en) | 2023-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101770902B1 (en) | Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof | |
| EP2736508A1 (en) | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor | |
| CN107243017A (en) | A kind of antibacterial balance gynecological gel and preparation method thereof | |
| Kenna et al. | Microbiology of chronic suppurative otitis media in children | |
| CN116236479B (en) | Use of SU3327 in the preparation of a medicament for enhancing the efficacy of polymyxin against bacterial infection | |
| CN110151752B (en) | Tea polyphenol composition and application thereof in preparation of anti-streptococcus suis medicines | |
| CN111588723B (en) | Gynecological disinfectant and preparation method thereof | |
| CN116687891B (en) | Application of phenyl selenium chloride | |
| US20060073156A1 (en) | Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract | |
| CN114149483B (en) | Antibacterial peptide composition and application thereof | |
| CN110711192A (en) | Use of tryptophan for enhancing gram-negative bacteria bactericidal effect | |
| Schiavo et al. | In vitro evaluation of the antimicrobial activity of a topical skin preparation containing 0.1% polyhexanide vs a topical skin preparation containing 1% silver sulfadiazine | |
| CN101849947B (en) | Composition of cefazedone sodium and tazobactam sodium and ratio of cefazedone sodium to tazobactam sodium | |
| KR102275801B1 (en) | Composition comprising cis-jasmone for inhibiting the formation of biofilm | |
| CN106880832A (en) | The new application of glutathione | |
| KR20200046287A (en) | Idnhibition of antibacterial resistance by 3',4'-difluoroquercetin and its derivative | |
| Craven et al. | Therapy of experimental staphylococcal mastitis in the mouse with cloxacillin and rifampicin, alone and in combination | |
| KR102342160B1 (en) | Composition comprising taxifolin for inhibiting the formation of biofilm | |
| CN101940573B (en) | Composition of cefamandole sodium and sulbactam sodium and mixture ratio thereof | |
| KR102441377B1 (en) | Composition comprising pectolinarin for inhibiting the formation of biofilm | |
| CN109395062B (en) | Female pudendum sterilization care solution | |
| CN101849949B (en) | Composition of cefapirin sodium and sulbactam sodium and ratio of cefapirin sodium to sulbactam sodium | |
| Muahiddah et al. | Effectiveness of Garcinia mangostana Mangosteen Peel Extract in Inhibiting Gram-Negative Bacteria in Lobster (Panulirus homarus) Aquaculture Waters | |
| CN116617231A (en) | Application of 2-amino naphthalene-embedded m-diazabenzene hydrobromide to enhancement of sterilization effect on gram-negative bacteria | |
| CN115414342A (en) | Application of fenbufen in preparation of medicine for killing gram-negative bacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |